alexa Development of Proteasome Inhibitors as Therapeutic Dru
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Development of Proteasome Inhibitors as Therapeutic Drugs

Samuel Troy Pellom Jr.1,2,3 and Anil Shanker1,4*
1Laboratory of Lymphocyte Function, Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN 37208, USA
2School of Graduate Studies and Research, Meharry Medical College, Nashville, TN 37208, USA
3Department of Microbiology and Immunology, School of Medicine, Meharry Medical College, Nashville, TN 37208, USA
4Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA
Corresponding Author : Anil Shanker
Department of Biochemistry and Cancer Biology
School of Medicine
Meharry Medical College 2005 Harold D West Basic Sciences Bldg 1005 Dr DB Todd Jr Blvd
Nashville, TN 37208, USA
Tel: 1-615 327 6460
Fax: 1-615 327 6442
E-mail: [email protected]
Received January 27, 2012; Accepted March 12, 2012; Published March 15, 2012
Citation: Pellom ST Jr., Anil Shanker (2012) Development of Proteasome Inhibitors as Therapeutic Drugs. J Clin Cell Immunol S5:005. doi:10.4172/2155-9899.S5-005
Copyright: © 2012 Pellom ST Jr., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


The proteasome is a multi-unit enzyme complex found in the cytoplasm and nucleus of all eukaryotic cells and is responsible for degradation of unneeded or damaged intracellular proteins by proteolysis, a chemical reaction that breaks peptide bonds. Proteasome inhibition presents a promising approach to cancer therapy by targeting the proteasome function in tumor cells. Delineating the success of bortezomib in the treatment of multiple myeloma and mantle cell lymphoma, this review explores various proteasome inhibitors, currently in development, as molecular targeting agents in the fight against cancer. Proteasome inhibitors can be used alone or in combination with other conventional cancer therapies to sensitize tumor cells to cell death by various mechanisms and improve therapeutic benefits.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version